Research shows that people with diabetes develop heart damage from a buildup of methylmalonic acid (MMA) even when their blood sugar is perfectly controlled and vitamin B12 levels are normal. According to Gram Research analysis of 12,751 diabetic adults, elevated MMA was significantly associated with subclinical heart damage and adverse outcomes independent of blood sugar control. The diabetes drug metformin protects the heart from MMA damage through multiple mechanisms, while vitamin B12 supplements do not help reduce MMA buildup in diabetic patients.
A major new study reveals that people with diabetes can develop hidden heart damage even when their blood sugar is perfectly controlled. Researchers found that a compound called methylmalonic acid (MMA) builds up in diabetic hearts and causes damage independently of blood sugar levels. The study of over 12,000 people showed that MMA accumulation happens because diabetes interferes with how the body breaks down certain amino acids from food. Surprisingly, taking vitamin B12 supplements doesn’t help, but the diabetes drug metformin actually protects the heart from MMA damage through multiple protective mechanisms. This discovery suggests doctors may need new strategies beyond blood sugar management to prevent heart problems in diabetes patients.
Key Statistics
A 2026 study of 12,751 diabetic adults published in Circulation Research found that elevated methylmalonic acid (MMA) was significantly associated with subclinical heart damage and adverse cardiovascular outcomes, even in patients with normal or high vitamin B12 levels and well-controlled blood sugar.
In diabetic mice, researchers found that branched-chain amino acid-restricted diets reduced MMA accumulation and alleviated diabetes-induced heart damage, suggesting dietary modification of amino acid intake may protect diabetic hearts.
A 2026 analysis showed that metformin, a common diabetes medication, mitigated MMA-induced heart damage in diabetic mice through dual mechanisms: activating cellular quality control systems and directly enhancing the enzyme that clears MMA from the body.
Vitamin B12 supplementation, even at high doses or using activated forms, failed to reduce MMA overload or prevent heart damage in diabetic mice, challenging the conventional approach to treating MMA elevation in diabetic patients.
The Quick Take
- What they studied: Whether a buildup of a chemical called methylmalonic acid (MMA) damages the heart in people with diabetes, even when their blood sugar is well-controlled
- Who participated: 12,751 adults with diabetes, plus laboratory studies in mice with diabetes-like conditions
- Key finding: People with diabetes who had elevated MMA in their blood showed signs of heart damage and worse health outcomes, regardless of their blood sugar control or vitamin B12 levels
- What it means for you: If you have diabetes, controlling blood sugar alone may not be enough to protect your heart. Your doctor might need to monitor additional markers and consider treatments like metformin that work through different mechanisms to prevent heart damage.
The Research Details
This was a large-scale research study combining two approaches. First, researchers analyzed blood samples and heart health data from 12,751 people with diabetes to see if MMA levels predicted heart problems. Second, they created mice with diabetes-like conditions and studied what happens in their hearts at the cellular level.
The researchers used advanced techniques to trace where MMA comes from in diabetic hearts, discovering it primarily comes from the breakdown of certain amino acids (isoleucine and valine) found in protein-rich foods. They also examined how diabetes changes the expression of a key enzyme called Mmut that normally breaks down MMA, and identified a specific molecule (miR-499) that appears to be responsible for this change.
Finally, they tested whether various treatments—including vitamin B12 supplements, dietary changes, and the diabetes drug metformin—could reduce MMA buildup and protect the heart.
This research approach is important because it bridges the gap between what happens in real patients and what happens in laboratory studies. By studying both human blood samples and mouse hearts at the molecular level, the researchers could identify the exact mechanisms causing the problem and test potential solutions. This multi-level approach gives confidence that findings in mice are likely relevant to human patients.
This study has several strengths: it included a very large number of human participants (12,751), used multiple advanced laboratory techniques to confirm findings, and tested results in animal models before drawing conclusions. The research was published in Circulation Research, a top-tier cardiovascular journal. However, the study is observational in humans (showing correlation, not proving cause-and-effect), so the human findings would benefit from follow-up clinical trials testing treatments directly.
What the Results Show
According to Gram Research analysis, elevated MMA in the blood was significantly linked to signs of heart damage in people with diabetes, even when their blood sugar was well-controlled and their vitamin B12 levels were normal or high. This was surprising because doctors traditionally view MMA elevation as a sign of vitamin B12 deficiency, which is rare in diabetic patients.
In the laboratory studies, researchers found that diabetic hearts had reduced levels of the Mmut enzyme that normally breaks down MMA. This reduction was caused by a molecule called miR-499, which is known to increase during high blood sugar episodes. Importantly, this MMA buildup happened early in the disease process, before obvious heart damage appeared, and persisted even after blood sugar was brought back to normal levels.
When researchers created mice lacking the Mmut enzyme, these mice developed severe heart damage and metabolic problems when given a high-fat diet and diabetes-inducing treatment. Conversely, when they boosted Mmut levels in diabetic mice using gene therapy, the hearts were protected from damage and MMA levels decreased significantly.
The study identified that MMA in diabetic hearts comes primarily from the breakdown of branched-chain amino acids (isoleucine and valine) found in protein-containing foods. When diabetic mice were fed a diet restricted in these amino acids, MMA buildup decreased and heart damage was reduced.
Vitamin B12 supplementation, even at high doses or using special activated forms, failed to reduce MMA buildup in diabetic mice or prevent heart damage. This was unexpected and suggests that MMA accumulation in diabetes works through a different mechanism than traditional B12 deficiency.
Metformin, a common diabetes medication, showed remarkable protective effects against MMA-induced heart damage through two separate mechanisms: it activated a cellular cleanup system (AMPK-dependent mitochondrial quality control) that helps the heart tolerate MMA, and it directly improved how well the Mmut enzyme works with vitamin B12 to clear MMA from the body. This finding is particularly important because metformin is sometimes avoided due to concerns about B12 deficiency, but this study suggests it may actually protect diabetic hearts.
This research challenges conventional understanding in several ways. Traditionally, doctors have viewed MMA elevation as a marker of vitamin B12 deficiency and assumed that B12 supplementation would solve the problem. This study shows that in diabetes, MMA accumulation is a separate phenomenon driven by metabolic changes in how the body processes amino acids, not by B12 deficiency. Additionally, while metformin has been associated with lower B12 levels in some patients, this research suggests the drug may have protective cardiovascular benefits that outweigh this concern. The finding that MMA damage persists even after blood sugar normalization also suggests that diabetes causes lasting changes in heart metabolism that aren’t reversed by glycemic control alone.
In human participants, the study shows that elevated MMA is associated with heart damage, but cannot definitively prove that MMA causes the damage (only that they occur together). The study didn’t directly test whether lowering MMA in humans improves heart health—this would require a clinical trial. Additionally, while the mouse studies provide mechanistic insights, results in mice don’t always translate perfectly to humans. The study also focused on specific populations and may not apply equally to all diabetic patients. Finally, the research doesn’t address whether other factors not measured in the study might explain some of the associations observed.
The Bottom Line
Based on this research, people with diabetes should: (1) Continue taking metformin if prescribed, as it appears to protect the heart through multiple mechanisms beyond blood sugar control; (2) Discuss with their doctor whether monitoring MMA levels might be useful in addition to standard blood sugar monitoring; (3) Consider whether moderating intake of branched-chain amino acids (found in high-protein foods, especially from animal sources) might be beneficial, though this requires further research; (4) Understand that achieving normal blood sugar levels alone may not fully protect the heart, and additional strategies may be needed. Confidence level: Moderate for metformin benefits (supported by multiple mechanisms in animal studies), Lower for dietary amino acid restriction (promising but needs human testing), and Lower for MMA monitoring (needs clinical validation).
This research is most relevant to people with type 2 diabetes, particularly those who have had diabetes for several years or have family history of heart disease. It’s also important for cardiologists and endocrinologists treating diabetic patients. People without diabetes or those with well-controlled type 1 diabetes should be less concerned about these specific findings. Importantly, this research doesn’t mean current diabetes treatments are wrong—it suggests they may need to be supplemented with additional protective strategies.
MMA accumulation appears to happen gradually over time in diabetes and may cause damage before obvious symptoms appear. The protective effects of metformin and dietary changes would likely take weeks to months to show measurable benefits in heart function. However, because MMA damage can be silent and progressive, starting protective measures early is important rather than waiting for symptoms to develop.
Frequently Asked Questions
Can you have heart damage from diabetes even if your blood sugar is controlled?
Yes. Research shows that methylmalonic acid (MMA) buildup damages diabetic hearts independently of blood sugar control. A 2026 study of 12,751 people found elevated MMA predicted heart damage even with normal blood sugar and B12 levels, suggesting additional protective mechanisms beyond glucose management are needed.
Does vitamin B12 help prevent heart problems in people with diabetes?
For MMA-related heart damage in diabetes, no. A 2026 study found that B12 supplementation, even at high doses, failed to reduce MMA buildup or prevent heart damage in diabetic mice. This suggests MMA accumulation in diabetes works differently than traditional B12 deficiency.
Is metformin safe for people with diabetes concerned about heart health?
Yes, and it may be particularly beneficial. Research shows metformin protects diabetic hearts from MMA-induced damage through two mechanisms: activating cellular cleanup systems and improving how the body clears MMA. This suggests metformin’s cardiovascular benefits may outweigh concerns about B12 levels.
What foods should people with diabetes avoid to prevent MMA buildup?
Foods high in branched-chain amino acids (isoleucine and valine)—particularly high-protein animal products—may contribute to MMA accumulation in diabetic hearts. A 2026 study found that branched-chain amino acid-restricted diets reduced MMA and heart damage in diabetic mice, though human studies are needed.
Can MMA damage in diabetes be reversed after it starts?
Research suggests early intervention is important. MMA damage appears to develop silently before obvious heart problems appear, and persists even after blood sugar normalization. This indicates that preventing MMA accumulation early through metformin use and dietary modifications may be more effective than trying to reverse established damage.
Want to Apply This Research?
- Track weekly average blood sugar readings alongside a simple heart health score (such as exercise minutes per week, resting heart rate, or shortness of breath episodes). This dual tracking helps users understand that blood sugar control alone isn’t sufficient for heart protection and motivates attention to other protective factors.
- Users with diabetes should set a goal to take their metformin consistently (if prescribed) and log this daily in the app, since the research shows metformin provides heart protection beyond blood sugar control. Additionally, users could track protein intake and aim to include more plant-based proteins while moderating high-protein animal products, as this may help reduce MMA buildup.
- Create a monthly check-in where users rate their energy levels, exercise capacity, and any symptoms like shortness of breath or fatigue. While these don’t directly measure MMA, they reflect overall heart health. Encourage users to discuss MMA testing with their doctor during annual checkups and log results in the app to track trends over time.
This research provides important insights into how diabetes affects the heart through mechanisms beyond blood sugar control, but it does not replace personalized medical advice. The human findings show associations between MMA levels and heart damage but do not prove direct causation. While animal studies suggest branched-chain amino acid restriction and metformin use may be protective, these approaches have not yet been tested in human clinical trials. Anyone with diabetes should continue following their doctor’s treatment plan and discuss these findings with their healthcare provider before making changes to diet, medications, or supplements. This article is for educational purposes and should not be used for self-diagnosis or self-treatment of heart disease or diabetes complications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.